Mechelen, Belgium; 30 May 2011 - Galapagos NV (Euronext: GLPG) announced today that Dr Ronald Brus has resigned from the Board of Directors.
Ronald Brus is President and Chief Executive Officer of Crucell. Dr Brus was a member of the Galapagos Board of Directors from 2000 until Galapagos' IPO in May 2005 and later rejoined the Board in April 2010. In February 2011, Crucell was acquired by Johnson & Johnson. Corporate policies at Johnson & Johnson stipulate that managers cannot serve as a member of any Board of Directors, and therefore Dr Brus resigned from Galapagos' Board effective 25 May 2011.
"We thank Ronald again for his contribution as a Board member," said Onno van de Stolpe, CEO of Galapagos. "Ronald has been involved with Galapagos from the start, and we have benefited from his strategic insights and experience as a successful biotech CEO. We wish him the best within Johnson & Johnson."
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company specialized in the discovery and development of small molecule and antibody therapies with novel modes-of-action. The Company is progressing one of the largest pipelines in biotech, with six programs in development and over 50 discovery programs. Through risk/reward-sharing alliances with GlaxoSmithKline, Lilly, Janssen Pharmaceutica, Roche and Servier, Galapagos is eligible to receive up to €2.5 billion in downstream milestones, plus royalties. The Galapagos Group has over 800 employees and operates facilities in seven countries, with global headquarters in Mechelen, Belgium. More info at: www.glpg.com
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
This release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," and "continues," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.